Approval · Notice of Compliance 34310 · 2024
SUMMIT ULTRA: Notice of Compliance 34310
Issued October 31, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 34310
- Date
- October 31, 2024
- Company
- Pendopharm Division Of Pharmascience IncMontreal, Quebec, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph as per advisement letter. Product Monograph reformatted to the Master Template.Update to the package insert. Update to package labels
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SUMMIT ULTRA | Not yet assigned | — |
Medicinal ingredients
- IBUPROFEN 400 MG per TAB
- METHOCARBAMOL 500 MG per TAB